Myths vs facts: CYP1A2 and Allergie

CYP1A2 is a cytochrome P450 enzyme primarily involved in metabolizing caffeine and certain drugs. Marketing often claims that specific CYP1A2 variants directly cause or worsen allergies. However, the scientific evidence is weak. Allergies are complex immune-mediated conditions influenced mainly by immune-related genes (e.g., HLA, IL-4, FCER1A) and environmental triggers. CYP1A2 may modulate the metabolism of environmental toxins or medications used in allergy treatment, but a direct causal link to allergy development is not established. Some studies report weak associations between CYP1A2 polymorphisms and asthma or hay fever, but results are inconsistent and not replicated. Therefore, the claim that consumer DNA tests for CYP1A2 can predict allergy predisposition is more myth than fact. Clinical relevance is low, and such tests should not be used for diagnosis or treatment decisions.